Testosterone and pre-androgens by age and menopausal stage at midlife: findings from a cross-sectional study
Abstract
BACKGROUND: Whether testosterone and the pre-androgens, androstenedione and dehydroepiandrosterone (DHEA) change at menopause remains uncertain.
METHODS: The Australian Women's Midlife Years Study recruited a nationally representative sample of 8096 women aged 40-69 years, between 27th October 2023 and 19th March 2024. Participants were excluded from providing a blood sample if pregnant, breastfeeding, using medications that affect sex hormone concentrations, or living over 100 km from a collection centre. Sex steroids were measured by liquid chromatography-tandem mass spectrometry and menopausal status was determined by the Stages of Reproductive Ageing Workshop (STRAW) + 10 criteria.
FINDINGS: Blood samples were provided by 1435 of the 5031 invited participants. After excluding participants with no menopause stage classification, abnormal thyroid function, hyperprolactinemia, bilateral oophorectomy, and an unreported pregnancy, 1104 participants, mean (SD) age 56.5 (8.5) years, were included in the main analysis. Median testosterone concentrations declined between the ages of 40-44 and 55-59 years (median (interdecile range) 0.56 (0.29-1.01) nmol/L vs 0.42 (0.21-0.79) nmol/L, p = 0.001 adjusted for BMI and smoking), reached a nadir at the age of 58-59 years, followed by a modest increase, and did not differ between the youngest group and participants aged 60-64 or 65-69 years. Median androstenedione and DHEA concentrations declined from the age of 40-44 years to 65-69…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 8,096 participants or records.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.